Literature DB >> 16140871

CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia.

Amos Toren1, Bella Bielorai, Jasmine Jacob-Hirsch, Tamar Fisher, Doron Kreiser, Orit Moran, Sharon Zeligson, David Givol, Assif Yitzhaky, Joseph Itskovitz-Eldor, Iris Kventsel, Esther Rosenthal, Ninette Amariglio, Gideon Rechavi.   

Abstract

Affymetrix human Hu133A oligonucleotide arrays were used to study the expression profile of CD133+ cord blood (CB) and peripheral blood (PB) using CD133 cell-surface marker. An unsupervised hierarchical clustering of 14,025 valid probe sets showed a clear distinction between the CD133+ cells representing the hematopoietic stem cell (HSC) population and CD133-differentiated cells. Two hundred forty-four genes were found to be upregulated by at least twofold in the CD133-positive cells of both CB and PB compared with the CD133-negative cells. These genes represent the hematopoietic "stemness," whereas the 218 and 304 upregulated genes exclusively in PB and CB, respectively, represent tissue specificity. Some of the stemness genes were also common to HSC genes found to be upregulated in several recently published studies. Among these common stemness genes, we identified several groups of genes that have an important role in hematopoiesis: growth factor receptors, transcription factors, genes that have an important role in development, and genes involved in cell growth. Sixteen selected stemness genes are known to be mutated or abnormally regulated in acute leukemias. It can be suggested that key hematopoietic stemness machinery genes may lead to abnormal proliferation and leukemia upon mutation or change of their expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140871     DOI: 10.1634/stemcells.2004-0317

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  28 in total

1.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

Authors:  Matthew G Guenther; Lee N Lawton; Tatiana Rozovskaia; Garrett M Frampton; Stuart S Levine; Thomas L Volkert; Carlo M Croce; Tatsuya Nakamura; Eli Canaani; Richard A Young
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

2.  Hematopoietic fingerprints: an expression database of stem cells and their progeny.

Authors:  Stuart M Chambers; Nathan C Boles; Kuan-Yin K Lin; Megan P Tierney; Teresa V Bowman; Steven B Bradfute; Alice J Chen; Akil A Merchant; Olga Sirin; David C Weksberg; Mehveen G Merchant; C Joseph Fisk; Chad A Shaw; Margaret A Goodell
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

3.  Transcriptional profiling of CD133(+) cells in coronary artery disease and effects of exercise on gene expression.

Authors:  Delong Liu; Alexander P Glaser; Sushmitha Patibandla; Arnon Blum; Peter J Munson; J Philip McCoy; Nalini Raghavachari; Richard O Cannon
Journal:  Cytotherapy       Date:  2011-02       Impact factor: 5.414

4.  Bottom up proteomics reveals novel differentiation proteins in neuroblastoma cells treated with 13-cis retinoic acid.

Authors:  Effie G Halakos; Andrew J Connell; Lisa Glazewski; Shuo Wei; Robert W Mason
Journal:  J Proteomics       Date:  2019-08-28       Impact factor: 4.044

5.  Re-evaluation of various molecular targets located on CD34+CD38-Lin- leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia.

Authors:  Yuping Cheng; Ming Jia; Yuanyuan Chen; Haizhao Zhao; Zebin Luo; Yongmin Tang
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

6.  Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity.

Authors:  Julia D Suerth; Tobias Maetzig; Martijn H Brugman; Niels Heinz; Jens-Uwe Appelt; Kerstin B Kaufmann; Manfred Schmidt; Manuel Grez; Ute Modlich; Christopher Baum; Axel Schambach
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

7.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

Review 8.  Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells.

Authors:  S Sell
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 5.739

9.  Expression of CD133 in acute leukemia.

Authors:  Fetnat M Tolba; Mona E Foda; Howyda M Kamal; Deena A Elshabrawy
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

10.  High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

Authors:  Christian Langer; Michael D Radmacher; Amy S Ruppert; Susan P Whitman; Peter Paschka; Krzysztof Mrózek; Claudia D Baldus; Tamara Vukosavljevic; Chang-Gong Liu; Mary E Ross; Bayard L Powell; Albert de la Chapelle; Jonathan E Kolitz; Richard A Larson; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2008-03-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.